BNTC vs. COLL, ZYME, NTLA, COGT, PHVS, PSTX, RCKT, AVBP, REPL, and IMNM
Should you be buying Benitec Biopharma stock or one of its competitors? The main competitors of Benitec Biopharma include Collegium Pharmaceutical (COLL), Zymeworks (ZYME), Intellia Therapeutics (NTLA), Cogent Biosciences (COGT), Pharvaris (PHVS), Poseida Therapeutics (PSTX), Rocket Pharmaceuticals (RCKT), ArriVent BioPharma (AVBP), Replimune Group (REPL), and Immunome (IMNM). These companies are all part of the "pharmaceutical products" industry.
Benitec Biopharma vs.
Collegium Pharmaceutical (NASDAQ:COLL) and Benitec Biopharma (NASDAQ:BNTC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, community ranking, dividends, analyst recommendations, institutional ownership, earnings and risk.
Collegium Pharmaceutical has a net margin of 14.78% compared to Benitec Biopharma's net margin of 0.00%. Collegium Pharmaceutical's return on equity of 104.67% beat Benitec Biopharma's return on equity.
In the previous week, Collegium Pharmaceutical and Collegium Pharmaceutical both had 5 articles in the media. Benitec Biopharma's average media sentiment score of 0.76 beat Collegium Pharmaceutical's score of 0.70 indicating that Benitec Biopharma is being referred to more favorably in the news media.
Collegium Pharmaceutical has a beta of 0.82, suggesting that its share price is 18% less volatile than the S&P 500. Comparatively, Benitec Biopharma has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500.
Collegium Pharmaceutical has higher revenue and earnings than Benitec Biopharma.
Collegium Pharmaceutical received 192 more outperform votes than Benitec Biopharma when rated by MarketBeat users. However, 65.44% of users gave Benitec Biopharma an outperform vote while only 65.26% of users gave Collegium Pharmaceutical an outperform vote.
52.2% of Benitec Biopharma shares are held by institutional investors. 4.0% of Collegium Pharmaceutical shares are held by company insiders. Comparatively, 1.3% of Benitec Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Collegium Pharmaceutical currently has a consensus target price of $43.60, suggesting a potential upside of 49.67%. Benitec Biopharma has a consensus target price of $24.43, suggesting a potential upside of 116.18%. Given Benitec Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe Benitec Biopharma is more favorable than Collegium Pharmaceutical.
Summary
Collegium Pharmaceutical and Benitec Biopharma tied by winning 8 of the 16 factors compared between the two stocks.
Get Benitec Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for BNTC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Benitec Biopharma Competitors List
Related Companies and Tools
This page (NASDAQ:BNTC) was last updated on 2/22/2025 by MarketBeat.com Staff
